ELI LILLY AND COMPANY Operating Leases, Future Minimum Payments, Due in Rolling after Year Five
ELI LILLY AND COMPANY (LLY) had Operating Leases, Future Minimum Payments, Due in Rolling after Year Five of $281.00 million as of 2018-12-31, per its 8-K filed 2019-10-24.
Discontinued › Notes › Leases
us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive · last filed 2019-10-24
- 2018-12-31: Operating Leases, Future Minimum Payments, Due in Rolling after Year Five $281.00M; Operating Leases, Future Minimum Payments, Due in Rolling after Year Five as first filed $299.50M.
- 2017-12-31: Operating Leases, Future Minimum Payments, Due in Rolling after Year Five $245.70M.
- 2016-12-31: Operating Leases, Future Minimum Payments, Due in Rolling after Year Five $339.40M.
| Period end | Operating Leases, Future Minimum Payments, Due in Rolling after Year Five | Operating Leases, Future Minimum Payments, Due in Rolling after Year Five as first filed |
|---|---|---|
| 2018-12-31 | $281.00M 8-K · filed 2019-10-24 | $299.50M 10-K · filed 2019-02-19 |
| 2017-12-31 | $245.70M 10-K · filed 2018-02-20 | |
| 2016-12-31 | $339.40M 10-K · filed 2017-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |